Driving the news: EssilorLuxottica said last week it would spend $1.5 billion to buy Supreme; it seems likely to accept a $5 billion investment from Meta; and is buying a controlling interest in ...

Supreme will have its own space within EssilorLuxottica’s house brand ... ResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025.

Despite a positive sales forecast for 2025, EssilorLuxottica's high valuation leaves no margin for error. Click here to find out why I rate ESLOY is a Hold.

J.P. Morgan analyst Chiara Battistini maintained a Buy rating on EssilorLuxottica SA (0OMK – Research Report) today and set a price target of €270.00. Discover outperforming stocks and invest ...